ClinConnect ClinConnect Logo
Search / Trial NCT06992726

Improvement of Fish Oil in Obesity With Mild Cognitive Impairment

Launched by WEIWEI MA · May 22, 2025

Trial Information

Current as of August 19, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the effects of fish oil supplements on people who are both obese and have mild cognitive impairment (MCI). Researchers want to see if taking fish oil, which contains a type of healthy fat called n-3 PUFA, can improve cognitive function, or thinking skills, in these individuals. The study will involve 88 participants aged between 35 and 80 years old who meet certain health criteria, including being diagnosed with obesity and MCI. Participants should not have taken fish oil or followed any special diets in the three months before the trial.

During the study, participants will be randomly divided into two groups: one will receive fish oil supplements, and the other will receive a placebo (a pill with no active ingredients) for a full year. Researchers will track changes in various areas, including diet, body composition, and cognitive function, at the beginning, after six months, and at the end of the 12-month period. It’s important to note that individuals with certain medical conditions, such as severe mental health issues or other serious health problems, will not be eligible to participate. This trial aims to provide valuable insights into how fish oil might help improve thinking skills in those facing obesity and cognitive challenges.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Meet the diagnostic criteria of obesity and MCI;
  • Age between 35 and 80 years old;
  • No dieting or stop dieting in the last 3 months, no fish oil supplements, or willing to stop self-administration of fish oil 3 months before the intervention;
  • Voluntarily participate in the program with informed consent, and sign the informed consent form.
  • Exclusion Criteria:
  • Those with neuropsychiatric disorders such as stroke, epilepsy, or schizophrenia;
  • Those with cognitive impairment caused by depression, thyroid disease, traumatic brain injury, drug or alcohol intoxication;
  • Those with a history of cerebrovascular disease or cognitive impairment caused by severe cardiac, hepatic, pulmonary, or renal impairment;
  • Those who are complete vegetarians and are unable to comply with the balanced dietary pattern;
  • Those who suffer from severe angina pectoris, asthmatic bronchitis, severe infections , systemic lupus erythematosus, malignant tumors, and other diseases that may affect one's dietary habits and life;
  • Coeliac disease with lipid malabsorption.

About Weiwei Ma

Weiwei Ma is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a strong emphasis on ethical practices and patient welfare, the organization focuses on developing and conducting high-quality clinical trials across various therapeutic areas. Leveraging a team of experienced professionals and robust methodologies, Weiwei Ma strives to facilitate the efficient translation of scientific discoveries into viable treatment options, ultimately aiming to improve patient outcomes and contribute to the broader healthcare landscape.

Locations

Patients applied

0 patients applied

Trial Officials

Ruiqi Mu

Principal Investigator

Capital Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported